Herein, we developed tumor-specific gene nanomedicines that utilize tumor-specific promoters to drive tumor cells to coexpress CXCL9 and αPD-L1 in situ, which effectively recruited T cells into tumors and enhanced the activation of tumor-infiltrating T cells. Here, CXCL9 is linked to neoplasm.